Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 04, 2016 20:20 ET | Source: Dynavax Technologies

Dynavax Provides Regulatory Update on HEPLISAV-B

BERKELEY, CA--(Marketwired - September 04, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation...
August 05, 2016 17:51 ET | Source: Dynavax Technologies

Dynavax Reports Second Quarter 2016 Financial Results

BERKELEY, CA--(Marketwired - August 05, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter and six months ended June 30, 2016.The Company...
August 05, 2016 17:31 ET | Source: Dynavax Technologies

Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B

BERKELEY, CA--(Marketwired - August 05, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the Vaccines and Related Biological Products Advisory Committee (VBRPAC) will...
June 11, 2016 11:00 ET | Source: Dynavax Technologies

Dynavax Presents New Efficacy Data on Hepatitis B Vaccine, HEPLISAV-B(TM), in Adults With Type 2 Diabetes at ADA Scientific Sessions

BERKELEY, CA--(Marketwired - June 11, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced preliminary results from a pivotal Phase 3 trial demonstrating that HEPLISAV-B [Hepatitis...
May 18, 2016 07:00 ET | Source: Dynavax Technologies

Dynavax to Present at Two Upcoming Investor Conferences

BERKELEY, CA--(Marketwired - May 18, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present at two upcoming investor conferences. Information relating to the...
May 09, 2016 09:00 ET | Source: Dynavax Technologies

Dynavax Reports First Quarter 2016 Financial Results

BERKELEY, CA--(Marketwired - May 09, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2016.The Company had $166.8...
April 27, 2016 07:00 ET | Source: Dynavax Technologies

Dynavax Receives Notification of PDUFA Extension for HEPLISAV-B to December 15, 2016

BERKELEY, CA--(Marketwired - April 27, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) will require additional time to...
April 18, 2016 16:02 ET | Source: Dynavax Technologies

Dynavax Presents Encouraging Data From Clinical Trial of Immuno-Oncology Product Candidate, SD-101

BERKELEY, CA--(Marketwired - April 18, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced encouraging additional data from Part 1 of a Phase 1/2 study (LYM-01) evaluating the...
April 18, 2016 16:02 ET | Source: Dynavax Technologies

Dynavax Presents Pivotal Phase 3 Data Showing HEPLISAV-B(TM) Provides Significantly Higher Protection Against Hepatitis B Than Engerix-B(R)

BERKELEY, CA--(Marketwired - April 18, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced results from HBV-23, a pivotal Phase 3 trial that provides head-to-head safety and...
April 04, 2016 07:00 ET | Source: Dynavax Technologies

Dynavax to Present Data From Pivotal Phase 3 HEPLISAV-B(TM) Trial

BERKELEY, CA--(Marketwired - April 04, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present HEPLISAV-B pivotal Phase 3 data at the National Foundation for...